XORTX Therapeutics (NASDAQ:XRTX) Posts Earnings Results

XORTX Therapeutics (NASDAQ:XRTX) released its quarterly earnings results on Friday. The technology company reported ($0.21) earnings per share for the quarter, FiscalAI reports.

XORTX Therapeutics Price Performance

Shares of NASDAQ XRTX traded up $0.18 during mid-day trading on Friday, hitting $1.10. 1,586,112 shares of the stock traded hands, compared to its average volume of 587,158. The company has a market cap of $2.00 million, a PE ratio of -0.40 and a beta of 0.83. XORTX Therapeutics has a twelve month low of $0.82 and a twelve month high of $3.60. The firm has a 50 day simple moving average of $1.47 and a two-hundred day simple moving average of $2.03.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XORTX Therapeutics in a research report on Monday, September 21st. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has an average rating of “Sell”.

XORTX Therapeutics Company Profile

XORTX Therapeutics Inc. (NASDAQ:XRTX) is a clinical-stage pharmaceutical company focused on developing therapies for conditions associated with dysregulated uric acid metabolism. The company’s research is centered on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of addressing kidney and other serious chronic diseases. XORTX’s development programs include XRx-008, an orally administered therapy being developed for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function.